Figure 7.

Antitumor Effects of T-01 In Vivo in Immunocompetent Mice

(A) Treatment schema. E.G7-OVA-nectin-1 was subcutaneously implanted into the right and left flanks of C57BL/6 mice. Mock or T-01 (2.0 × 10⁶ PFUs) was injected into the established right tumor on days 0 and 3. The tumor size was measured every 2 or 3 days. (B) Tumor growth curves (n = 8). Arrows indicate injection of mock or T-01. The data are shown as the mean ± SE. Statistical analysis was conducted using a two-tailed unpaired t test. ∗p < 0.05. (C) Tetramer staining of tumor-infiltrating lymphocytes (TILs) and spleen cells. TILs from the T-01-injected right-side tumor, those from the T-01-non-injected left-side tumor, and spleen cells were isolated 10 days after the second injection of mock or T-01. The frequency (%) of H-2K^b OVA tetramer-positive cells among CD8⁺ T cells was measured by flow cytometry. The statistical differences of the tetramer-positive cells between mock- or T-01-treated mice were analyzed (n = 4) (upper panels). The data are shown as the mean ± SE. Statistical analysis was conducted using a two-tailed unpaired t test. ∗∗∗p < 0.001. Lower panels show representative data of TILs stained with the OVA tetramer.